Fatty acids induce a pro-inflammatory gene expression profile in Huh-7 cells that attenuates the anti-HCV action of interferon

Journal of Interferon and Cytokine Research

Volumn 35, Issue 5, 2015, Pages 392-400

  Tse, Edmund ^a   Helbig, Karla J ^a   Van Der Hoek, Kylie ^a   McCartney, Erin M ^a   Van Der Hoek, Mark ^b   George, Jacob ^c   Beard, Michael R ^a,d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b SA PATHOLOGY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d University of Adelaide   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; OLEIC ACID; PALMITIC ACID; PEGINTERFERON ALPHA; TOLL LIKE RECEPTOR 2; TRANSCRIPTOME; FATTY ACID; INTERFERON;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TREATMENT FAILURE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEPATITIS; HEPATITIS C VIRUS; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID STORAGE; LIVER CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEATOSIS; VIRUS REPLICATION; CELL LINE; CHRONIC HEPATITIS C; CLUSTER ANALYSIS; DRUG EFFECTS; DRUG POTENTIATION; FATTY LIVER; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; METABOLISM; PHYSIOLOGY;

HEPATITIS C VIRUS;

CELL LINE; CLUSTER ANALYSIS; DRUG SYNERGISM; FATTY ACIDS; FATTY LIVER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; NF-KAPPA B; OLEIC ACID; PALMITIC ACID; TOLL-LIKE RECEPTOR 2; TRANSCRIPTOME; VIRUS REPLICATION;

EID: 84928947939     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0165     Document Type: Article

References (40)

1. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, Poniachik J. 2004. Increase in long-chain poly-unsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 106(6):635-643.
2. Baffy G. 2009. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol 51(1):212-223.
3. Baylin A, Kabagambe EK, Siles X, Campos H. 2002. Adipose tissue biomarkers of fatty acid intake. Am J Clin Nutr 76(4):750-757.
4. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. 2004. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40(6):1387-1395.
5. Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. 2011. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 54(1):133-144.
6. Day CP, James OF. 1998. Steatohepatitis: a tale of two "hits"? Gastroenterology 114(4):842-845.
7. Gomez-Lechon MJ, Donato MT, Martinez-Romero A, Jimenez N, Castell JV, O'Connor JE. 2007. A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact 165(2):106-116.
8. Goossens N, Negro F. 2014. The impact of obesity and metabolic syndrome on chronic hepatitis C. Clin Liver Dis 18(1): 147-156.
9. Gunduz F, Aboulnasr FM, Chandra PK, Hazari S, Poat B, Baker DP, Balart LA, Dash S. 2012. Free fatty acids induce ER stress and block antiviral activity of interferon alpha against hepatitis C virus in cell culture. Virol J 9:143.
10. Helbig KJ, Eyre NS, Yip E, Narayana S, Li K, Fiches G, McCartney EM, Jangra RK, Lemon SM, Beard MR. 2012. The antiviral protein viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 5A. Hepa-tology 54(5):1506-1517.
11. Helbig KJ, Ruszkiewicz A, Lanford RE, Berzsenyi MD, Harley HA, McColl SR, Beard MR. 2009. Differential expressionofthe CXCR3 ligandsin chronic hepatitisCvirus (HCV) infection and their modulation by HCV in vitro. J Virol 83(2):836-846.
12. Helbig KJ, Ruszkiewicz A, Semendric L, Harley HA, McColl SR, Beard MR. 2004. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. Hepatology 39(5):1220-1229.
13. Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, Hall P, Khan M, George J. 2003. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 38(2):420-427.
14. Joshi-Barve S, Barve SS, Amancherla K, Gobejishvili L, Hill D, Cave M, Hote P, McClain CJ. 2007. Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology 46(3):823-830.
15. Khabar KS, Al-Zoghaibi F, Murayama T, Matsushima K, Mu-kaida N, Siddiqui Y, Dhalla M, Al-Ahdal MN. 1997. Inter-leukin-8 selectively enhances cytopathic effect (CPE) induced by positive-strand RNA viruses in the human WISH cell line. Biochem Biophys Res Commun 235(3):774-778.
16. Loomba R, Sanyal AJ. 2013. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10(11):686-690.
17. Maher JJ, Leon P, Ryan JC. 2008. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology 48(2):670-678.
18. McCartney EM, Semendric L, Helbig KJ, Hinze S, Jones B, Weinman SA, Beard MR. 2008. Alcohol metabolism increases the replication of hepatitis C virus and attenuates the antiviral action of interferon. J Infect Dis 198(12):1766-1775.
19. Metz P, Reuter A, Bender S, Bartenschlager R. 2013. Inter-feron-stimulated genes and their role in controlling hepatitis C virus. J Hepatol 59(6):1331-1341.
20. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Oh-nishi H, Olefsky JM, Brenner DA, Seki E. 2010. Toll-like receptor 9 promotes steatohepatitis by induction of interleu-kin-1beta in mice. Gastroenterology 139(1):323-334.e7.
21. Miura K, Seki E, Ohnishi H, Brenner DA. 2011. Role of Tolllike receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol Res Pract 2010:362847.
22. Miura K, Yang L, van Rooijen N, Brenner DA, Ohnishi H, Seki E. 2013. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology 57(2):577-589.
23. Moschen AR, Fritz T, Clouston AD, Rebhan I, Bauhofer O, Barrie HD, Powell EE, Kim SH, Dinarello CA, Bartenschlager R, Jonsson JR, Tilg H. 2011. Interleukin-32: a new proin-flammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis. Hepatology 53(6):1819-1829.
24. Nguyen MT, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A, Liu-Bryan R, Glass CK, Neels JG, Olefsky JM. 2007. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 282(48):35279-35292.
25. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, Heaton S, Conrad A, Pockros PJ, McHutchison JG. 2004. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 40(3):484-490.
26. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, Abid K, Negro F, Dreux M, Cosset FL, Bartenschlager R. 2006. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 103(19):7408-7413.
27. Polyak SJ, Khabar KS, Paschal DM, Ezelle HJ, Duverlie G, Barber GN, Levy DE, Mukaida N, Gretch DR. 2001a. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 75(13):6095-6106.
28. Polyak SJ, Khabar KS, Rezeiq M, Gretch DR. 2001b. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol 75(13):6209-6211.
29. Poustchi H, Negro F, Hui J, Cua IH, Brandt LR, Kench JG, George J. 2008. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 48(1):28-34.
30. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J. 2003. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38(1):75-85.
31. Preiss S, Thompson A, Chen X, Rodgers S, Markovska V, Desmond P, Visvanathan K, Li K, Locarnini S, Revill P. 2008. Characterization of the innate immune signalling pathways in hepatocyte cell lines. J Viral Hepat 15(12):888-900.
32. Ricchi M, Odoardi MR, Carulli L, Anzivino C, Ballestri S, Pinetti A, Fantoni LI, Marra F, Bertolotti M, Banni S, Lo-nardo A, Carulli N, Loria P. 2009. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol 24(5):830-840.
33. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, All-man M, Wallace M. 2007. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of nonalcoholic steatohepatitis. J Hepatol 47(4):571-579.
34. Senn JJ. 2006. Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J Biol Chem 281(37):26865-26875.
35. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. 2006. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116(11):3015-3025.
36. Theodore D, Fried MW. 2000. Natural history and disease manifestations of hepatitis C infection. Curr Top Microbiol Immunol 242:43-54.
37. Thompson AJ, Colledge D, Rodgers S, Wilson R, Revill P, Desmond P, Mansell A, Visvanathan K, Locarnini S. 2009. Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther 14(6):797-808.
38. Tiniakos DG, Vos MB, Brunt EM. 2010. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 5:145-171.
39. Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS. 2012. Kuppfer cells trigger nonalcoholic stea-tohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production. J Biol Chem 287(48):40161-40172.
40. Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, Pawlotsky JM, Zeuzem S, Schalm SW, Verheij-Hart E, Negro F, Missale G, Neumann AU, Hellstrand K. 2007. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat 14(1):29-35.